Purpose: To determine the compliance to the treatment in patients with neovascular Age Related Macular Degeneration in whom intravitreal injection of ranibizumab was recommended.

Method: The files of the patients diagnosed as neovascular AMD were reviewed retrospectively. The last 100 consecutive patients' intravitreal ranibizumab injection was recommended were included in the study. Treatment regimen was intravitreal injections as needed after three consecutive monthly injections. Demographic data and ocular characteristics were recorded. The number of patients continuing the treatment and reasons of failure to continue treatment were questioned. The patients discontinued the follow-up were interviewed by phone call.

Results: The genders of patients were 51 women and 49 men. Mean age of patients was 70.41 ± 9.86 years. Eighty-seven patients completed three consecutive injections. Twenty patients failed to continue the PRN strategy with monthly follow-ups after three consecutive monthly injections at one year. Overall 33% of patients did not able to maintain the intravitreal ranibizumab treatment for one year. The main reasons to discontinue the treatment were fear of injection, to meet their fate calmly, inability to afford every visit each month and economical. Sub-analysis for the reasons of noncompliance of the patients lost during follow-up was carried out.

Conclusion: Although the patients with neovascular AMD accepting intravitreal ranibizumab injections at the baseline of the treatment shows high compliance rate, relatively important proportion of these patients are lost during follow-up at the first year due to some reasons stated in the current report.